The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Open accessAbstract
Inhibiting protein function selectively is a major goal of modern drug discovery. Here, we report a previously understudied benefit of small molecule proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degradation. Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded. The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases. In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degradation. This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-molecule inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, possible off-target effects may arise from the E3 ligase ligand side, such as the degradation of GSPT1 in this work and others[42–44].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [42]
In the citing paper
“In addition, Bondeson et al. showed that a promiscuous ligand for about 50 kinases could induce only a subset of its targets for degradation when converted into a PROTAC45.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [45]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [65]
In the citing paper
“Multiple studies have reported that the stability of the E3-degrader-POI ternary complex may influence degradation kinetics and selectivity, and may be a more reliable predictor for degradation than target engagement alone (Bondeson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Bondeson et al., 2018
In the citing paper
“The propensity of different E3 ligases to ubiquitinate specific proteins has been reported to vary in the literature (Bondeson et al., 2018; Smith et al., 2019) and variation is attributed to the unique protein-protein interactions that may form between the E3 ligase and target.”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Bondeson et al., 2018
In the citing paper
“PROTACs are small molecules with two functional ends, wherein one end binds to the protein of interest while the other binds to an E3 ubiquitin ligase (2, 3), bringing the ubiquitin ligase to the target protein, leading to its ubiquitination and subsequent degradation by the proteasome.”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [2]
In the citing paper
“Addition of a linker with a moiety to recruit either VHL or CRBN reduced foretinib’s inhibition for several of these kinases, but overall both PROTACs retained broad non-selective inhibition.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“It has been shown that a PROTAC’s ability to bind the target protein is not the primary determinant of whether efficient degradation occurs; rather, it has been suggested that formation of the ternary complex is limiting (i.e., the ability of the PROTAC to simultaneously bind both the target protein and the E3 ligase) 20, 22.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Moreover, the extent to which different kinases were degraded was not simply a reflection related to how tightly the PROTAC bound the kinase, since inhibition constants were not correlated with cellular degradation 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Using a competitive binding assay, foretinib itself was first shown to inhibit at least a quarter of the human kinome 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“Remarkably, however, cellular treatment revealed that certain kinases were degraded much more efficiently by the VHL-recruiting PROTAC, while others were degraded more efficiently by the CRBN-recruiting PROTAC 20.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“It has further been shown that PROTAC selectivity does not necessarily mimic that of its target-binding warhead, but rather depends sensitively on the linker 20, 23, 24, 33”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [20]
In the citing paper
“PROTACs may also benefit from cooperative PPIs between the E3 ligase and the POI. This can have the advantages of improved potency49 and selectivity50.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [49]
In the citing paper
“the pairing of VHL versus CRBN for a given target can result in different degradation efficiencies49, as was first observed when targeting the fusion oncogene BCR–ABL by PROTACs118.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [49]
In the citing paper
“In addition, many PROTACs are not completely selective and can degrade proteins other than their desired targets [7, 90, 204, 205].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [204]
In the citing paper
“A major advantage of VHL-based PROTACs is their target-specificity [44, 53].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“high binary binding affinities are not necessarily needed to result in efficient degradation of a target protein [53]”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“using the same promiscuous kinase inhibitor as a warhead, the CRBN-based PROTAC degrades more kinases than the VHL-based PROTAC [53].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [53]
In the citing paper
“and several PROTACs have been found to be more selective than the inhibitor from which they were derived 12,28,29,30 ,”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. J. W. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,867
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 965
Chiang, C. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735998607.793561779
Che, Y. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737014723.793569231
Copeland, R. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733651684.793549798
Huang, Y., Yokoe, H., Kaiho-Soma, A., Takahashi, K., Hirasawa, Y., Morita, H., Ohtake, F., & Kanoh, N. (2021) · doi:10.33774/chemrxiv-2021-8cp0q
Doller, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00057-8
Targeted Protein Degradation in Antiviral Drug Discovery
de Wispelaere, M., & Yang, P. L. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch14
Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery
Martinelli, P., Kofink, C. C., Boeck, G., Weinstabl, H., & Koegl, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch11
Taming the Beast: How to Optimize DMPK–PD Properties of Oral Degraders
Rynn, C., Vyver, A. J. V. D., Walz, A., Cantrill, C., & Wittwer, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch12
A Structural and Biophysical Perspective of Degrader Activity Through Ternary Complex Formation
Gadd, M. S., & Aublette, M. C. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch4
Heterobifunctional Degraders for the Treatment of Lymphoid Malignancies
Gollerkeri, A. M., Gollob, A. J., & Mainolfi, N. (2023) · doi:10.1002/9781119819950.ch26
Dependency of 3D chromatin folding on RNA polymerase II at different cell cycle stages
Übelmesser, N. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9998
Kodadek, T. J. (2023) · Angewandte Chemie · doi:10.1002/ange.202316726
Development of a PROTAC Targeting Chk1Preprint
Chowdhury, S. R., Chuong, P., Mgbemena, V. E., & Statsyuk, A. V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.30.573733
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Discovery of Novel Egfr-Protacs Overcoming Various Types of Acquired Drugs ResistantPreprint
Du, Y., Shi, S., Chen, S., He, Y., Xu, W., Wu, D., Tian, Y., Kong, M., He, J., Xie, W., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4769468
Newman, J. A., Gavard, A. E., Imprachim, N., Aitkenhead, H., Sheppard, H. E., Clarke, P. A., Hossain, M. A., Temme, L., Oh, H. J., Wells, C. I., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.06.597736
Defining degradability landscape of protein degradersPreprint
Elemento, O., & Du, W. (2024) · Research Square · doi:10.21203/rs.3.rs-4254960/v1
Targeted Protein Degradation Technology: A Novel Strategy for Cancer Therapy
Xu, A., & Reynolds, E. (2024) · Journal of Student Research · doi:10.47611/jsrhs.v13i1.6455
Clinical Development of PROTACs
Dubey, A., Pal, K., & Gota, V. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_9
Structural Considerations and Chemistry of PROTACs
Wahi, A., Jadhav, H. R., Thakur, S., Dev, S., Mohanty, P., & Jain, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_3
Xia, J., Norris, J. K. S., Mackinnon, M., & Butterworth, S. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100015 · Cited by 1
The emergence of pan-KRAS drugs
McConnell, D. B., & Kraut, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00019-x
Kamaraj, R., Nencka, R., & Pávek, P. (2024) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2024.10.002
Heterobifunctional proteomimetic polymers for targeted protein degradationPreprint
Wang, M. M., Truica, M. I., Gattis, B. S., Oktawiec, J., Sagar, V., Basu, A. A., Bertin, P. A., Zhang, X., Abdulkadir, S. A., & Gianneschi, N. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.07.641543
Hanl, M., Feller, F., Honin, I., Tan, K., Miranda, M., Schäker-Hübner, L., Bückreiß, N., Schiedel, M., Gütschow, M., Bendas, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.31.646177
The next frontier in drug discovery: Unveiling the pharmacological potential of proximity inducers
Holmberg‐Douglas, N., Keenan, K. N., de Turiso, F. G.-L., Chekler, E. P., Shanmugasundaram, V., Riggs, J. R., & Zapf, C. W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00018-2
Targeted Protein Degradation of Metalloenzymes
O’Herin, C., & Cohen, S. M. (2025) · Wiley eBooks · doi:10.1002/0471266949.bmc303
Androgen receptor degraders as antiprostate cancer agents
Chen, Q. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23585-6.00011-x
Annear, J. W., Nutt, M. J., Flematti, G. R., Rosenbluh, J., & Stewart, S. G. (2025) · Tetrahedron Letters · doi:10.1016/j.tetlet.2025.155692
Abdelsalam, M. A. M., Halilovic, M., Ashry, R., Nassar, H., Schmidt, M., Krämer, O. H., & Sippl, W. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5336245
New modalities: Drugging the undruggable GPCR targets
Zawadzki, P., Graczyk, P. P., & Staroń, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00030-3
Generative AI Framework SynGlue for the Rational Design of Clinically relevant Protein DegradersPreprint
Solanki, S., Mohanty, S. K., Satija, S., Chauhan, S., Bandaru, N. V. M. R., Dukare, S., Tiwari, N. K., Kumar, R. N., Aravind, A. B., Mukherjee, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.28.672835
Therapeutic Potential of STK17A Targeted TherapiesPreprint
Feng, Y., Ouaakki, H., Bravo, E., & Taylor, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5669235
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Liu, Y., Wu, J., Chen, D., & Han, L. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00381
Additional file 1 of Single-domain antibody-based protein degrader for synucleinopathies
Jiang, Y., Lin, Y., Tetlow, A. M., Pan, R., Ji, C., Kong, X., Congdon, E. E., & Sigurdsson, E. M. (2024) · Figshare · doi:10.6084/m9.figshare.26727922
Additional file 2 of Single-domain antibody-based protein degrader for synucleinopathies
Jiang, Y., Lin, Y., Tetlow, A. M., Pan, R., Ji, C., Kong, X., Congdon, E. E., & Sigurdsson, E. M. (2024) · Figshare · doi:10.6084/m9.figshare.26727925
CBL ubiquitin ligase targets translation as a degrader E3
Wicks, A. T., Buetow, L., Suzuki, T., Schmidt, T., Lilla, S., Macmillan-Jones, A. L., Turney, J., Gohlke, A., Bushell, M., Hock, A., et al. (2025) · Chemical Science · doi:10.1039/d5sc06141e
Dual Target E3 Ligase Ligands: A New Way to Overcome Drug Resistance
潘, 相. (2026) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2026.141006
Chen, A., Huang, X., Liao, E., & Shao, Y. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07727-9
Gerritz, S. W., Campbell, A.-M., Klug, D. M., & Sherman, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00074-1
Cornu, M., Pezeril, J., Guedeney, N., Paysant, H., Lemaitre, T., Schwalen, F., Florent, R., N’Guyen, J., Corvaisier, S., Since, M., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100336
Large‐Scale Profiling of Kinase Degradation by Using Norbornene‐Based Hydrophobic Tag (HyT) Strategy
Gu, M., Miao, F., Peng, L., Sun, J., Chen, P., Yang, F., Yan, J., Gao, L., Lu, X., Yao, S. Q., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.2319269
Large‐Scale Profiling of Kinase Degradation by Using Norbornene‐Based Hydrophobic Tag (HyT) Strategy
Gu, M., Miao, F., Peng, L., Sun, J., Chen, P., Yang, F., Yan, J., Gao, L., Lu, X., Yao, S. Q., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.2319269
Wang, X., Song, J., Zhao, Y., Li, W., Li, J., Xu, X., Liu, W., Tao, F., & Xu, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108239 · Cited by 2
Olsson, N., Gaun, A., Villa, S., Jackson, K. L., Fitzgerald, M. E., McAllister, F. E., Stokoe, D., Nile, A. H., & Bersuker, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.23.727405
Holdaway, J. A., Saini, L., Coil-Otto, R., Nayyab, S., Taghavi, M., Visconti, P. E., & Georg, G. I. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03689
Research progress of proteolysis-targeting chimeras in viral hepatitis drug discovery
Hao, X., Wang, Y., Huang, G., Lin, C., Zhao, P., Zhi, W., Li, X., Qi, P., & Liu, P. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1810498
Research Progress of Proteolysis‐Targeting Chimera Technology and Its Linkers in Cancer Therapy
Yang, J., & Zhang, X. (2026) · ChemMedChem · doi:10.1002/cmdc.70291
On‐Demand Activatable PROTACs for Targeted Protein Degradation
Guo, C., Ren, Z., Wu, X., Yao, Q., & Gao, Y. (2026) · Chemistry - A European Journal · doi:10.1002/chem.71283
Liu, M., Wang, L., Pan, Z., Ye, J., Wu, F., He, G., & Chen, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119131
Zhou, Y., Cao, Y., Ma, X., Yang, H., Tian, S., Zhu, C., Tang, Y., Zhang, R., Onuchic, J. N., & Bai, F. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103420
Linker attachment points: “finishing touch” in PROTAC design
jiang, Q., Shi, H.-S., Zhao, C.-S., Wang, Z.-Y., Yu, M.-M., Zhang, X.-Y., & Liu, C.-J. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00346j
A quantitative approach for defining the degradability landscape of protein degraders
Du, W., Boni, L. D., Hopkins, B. D., & Elemento, O. (2026) · Nature Communications · doi:10.1038/s41467-026-75591-8
Liu, S., Wang, Y., Zhang, Y., Chen, K., Wang, Y.-N., Zhang, Q., & Jin, X. (2026) · Journal of Ginseng Research · doi:10.1016/j.jgr.2026.101112
Li, C., Wang, X., He, A., Bao, T., Zhuang, W., He, C., & Yang, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070887
Bravo, E., Pastrana, C. C., Lamkin, E. N., Ciurko, K., & Taylor, J. (2026) · Cells · doi:10.3390/cells15151383
Optimizing CRBN-ligands for optical targeted protein degradation
Flores, J. A., DiNardi, R. G., Burslem, G. M., Cheng, T., & Trauner, D. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00266h
Self-citationHailu, G. S., Fabbrizi, E., Mancini, A., Fiorentino, F., Mai, A., & Rotili, D. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104769
Ren, S., Zhang, Y., Hao, R., Yuan, J., Chi, M., Cai, W., Gu, W., Huang, Y., Yuan, Y., Chen, X., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110388
Integrative Proteomics and Ubiquitomics Reveal on-Targets and off-Targets of PROTAC dBET1
Wen, H., Liu, H., Liu, J., Yang, B., Dai, J., Chang, L., Li, Y., Zhang, Y., Yu, L., & Xu, P. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c00787
Chemical tools for BAZ2A/B biology: discovery of dual and BAZ2B-selective PROTAC degraders
Cheng‐Sánchez, I., Gosselé, K. A., Palaferri, L., Krummhaar, M., Laul, E., Ciulli, A., & Nevado, C. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00244g
Targeted protein degradation: mechanistic diversity, therapeutic expansion, and clinical translation
Wang, C., Guo, Z., Liu, Y., Gao, Q., Wang, Q., Liu, Y., & Liu, Y. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127323
Zhu, R., Guo, G., Li, L., & Luo, S. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109358
Meng, X., Ma, M., Wang, X., Ma, S., Li, Z., Wu, T., Wang, S., & Qin, C. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.020
Chemically Induced Proximity in Biological Modulation
Jin, X., Zhou, C., & Zhang, X. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00121
Discovery and characterization of PGC-01: An effective GSDMD-targeting PROTAC
Wang, Q., Hou, R.-Y., Shua, Y.-X., Xu, Y.-F., Bian, W., Xiao, W., Chen, Y., Zhou, B.-Y., Gao, Y., Liu, L., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119294
Chan, A. M., Eberly, C. L., Goodis, C. C., Nordquist, E. B., Weldemariam, M. M., Carter‐Cooper, B., Pogash, S., Lapidus, R. S., Kane, M. A., MacKerell, A. D., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00232
Li, Y., Du, Y., Deng, P., Yang, Y., Wu, Y., Sun, X., Chen, Q., Yang, J., Zhu, Q., Gan, Z., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110495
High-Throughput Screen for Candidate PROTAC Identification
Chen, X., & Zhu, C. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_841
An artificial antibody-based modular platform for targeted degradation of cellular membrane proteins
Deng, J., Liu, J., Chu, Z., Guo, Y., Liu, Y.-Y., Gao, T., Wang, Y., Lou, C., Tang, H., Wang, H., et al. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103187
Ni, X., Li, M., Tang, J., Qi, Z., Zhou, Y., Liao, Z., Song, Y., Miao, Q., Zhang, Z., Jiang, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01893
Discovery of PROTACs recruiting the E3 ligase CHIP
Masuda-Ozawa, T., Tomoshige, S., Hayakawa, E., Sato, S., Ohgane, K., Ohtake, F., & Ishikawa, M. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00124f
Fitness criteria for PROTACs as chemical probes: principles and applications
Sturbaut, M., & Ciulli, A. (2026) · Essays in Biochemistry · doi:10.1042/ebc20260006 · Cited by 1
Chemoproteomics in covalent cancer drug discovery
Ong, J.-P., Dalziel, M., Johns, D., Zhu, J., & Bertoldo, J. B. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104817
Kou, P., O’Brien, M. N., Latham, A. P., Chiang, C., Zhang, D., Pang, J., Cui, Y., Zang, N., Tang, S., Nagapudi, K., et al. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127485
Recent Advances in Nanotechnology for Targeted Protein Degradation
Xu, M., Yang, Y., Chen, J., Wang, X., Wang, S., Ma, F., & Shi, L. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c12624
Overview of screening assays used to evaluate PROTACs for cancer treatment
Obidat, R., Reyes-Martinez, J., AlRawashdeh, S., Loredo-Calderón, E. L., & Velázquez‐Martínez, C. A. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104822
Okitsu, K., Tsuji, G., & Demizu, Y. (2026) · Bioorganic & Medicinal Chemistry · doi:10.2139/ssrn.7576374
Nagmoti, S., Kadam, E., Sakle, N. S., Kapare, H. S., & Karwa, P. N. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04970-1
Wang, T., Ji, C., & Zhao, T. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1967704
Identification of selective FGFR2/4 degraders with potent antiproliferative activity
Zhang, J., Zhang, X., Li, Y., Jin, S., Liu, B., Wu, Y., Pan, Y., Li, G., Lu, C., Shao, H., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119431
Zhang, Y., Zhu, L., Xia, L., Cheng, H., Zhu, W., & Wang, H. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101378
Long, M. J. C., Birkby, L., & Aye, Y. (2026) · FEBS Journal · doi:10.1111/febs.70754
BindingDB (2026) · UC San Diego · doi:10.7270/q2xg9wzj
BindingDB (2024) · UC San Diego · doi:10.7270/q25b06wr
BindingDB Entry 50017954: PROTACs to address the challenges facing small molecule inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q2p55sm1
BindingDB (2025) · UC San Diego · doi:10.7270/q2b85dsn
BindingDB Entry 50019814: Annual review of KRAS inhibitors in 2022.
BindingDB (2024) · UC San Diego · doi:10.7270/q2sx6jm1
Metadata
- Authors
- Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M.
- Affiliations
- Yale University (US)
- Arvinas (United States) (US)
- Corresponding author
- Crews, Craig M.
- ORCID
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 25
- Issue
- 1
- Pages
- 78-87.e5
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- PMC
- PMC5777153
- OpenAlex
- W2767856718
- Cited by
- 923
- References
- 50
- Citations by year
- 2026: 104 · 2025: 133 · 2024: 147 · 2023: 104 · 2022: 110 · 2021: 110 · 2020: 109 · 2019: 72 · 2018: 29
- FWCI
- 23.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell chemical biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NCI (F99 CA212229-02, R50 CA211252-02)
- Leukemia and Lymphoma Society Career Development
- NIH (R35CA197589)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, protein degradation, E3 ubiquitin ligase, cereblon, VHL, protein-protein interaction, ternary complex stability, PROTAC design, undruggable proteins, ubiquitination, proteasome
- MeSH terms
- Humans, Drug Design, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Protein Kinase Inhibitors, Small Molecule Libraries, Ubiquitination, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
